Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05174312 · ClinicalTrials.gov registry record · NA
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
A NA study of Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 16
- Study locations
NCT05174312: Completed NA study of Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular.
NCT05174312 is a NA study of Acute Decompensated Heart Failure that has completed, run by Reprieve Cardiovascular. The registered enrollment target is 100 participants, below the 451-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (78% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05174312, a NA study of Acute Decompensated Heart Failure, has completed, sponsored by Reprieve Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 16
- Study locations
Study Summary
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.
Primary Outcome
Primary efficacy endpoint is total urine sodium output at 24 hours post-treatment initiation.
Conditions Studied
Interventions
- DEVICE Reprieve Decongestion Management System
- DRUG Diuretic
Study Locations (16)
North Carolina
- Duke University Hospital - Durham
- Cone Health - Greensboro
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Missouri
- St. Louis VA - St Louis
- Washington University - St Louis
Ohio
- The Lindner Research Center at Christ Hospital - Cincinnati
- Ohio State University Hospital - Columbus
South Carolina
- Medical University of South Carolina - Charleston
- Prisma Health - Columbia
Texas
- Ascension Texas Cardiovascular - Austin
- Baylor Scott & White - Dallas
Alabama
- Eastern Shore Research Institute - Fairhope
California
- University of California Irvine - Irvine
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2025-01-10 |
| Phase | NA |
What the finished NCT05174312 record still lists
NCT05174312 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 451-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Acute Decompensated Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Reprieve Decongestion Management System is the first listed.
NCT05174312 lists 16 locations in 10 states (North Carolina, Missouri, Ohio).
Frequently Asked Questions
What is clinical trial NCT05174312 about?
NCT05174312 is a clinical study titled "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)". The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more...
What is the current status of trial NCT05174312?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2022-07-11. Estimated completion is 2025-01-10.
What conditions does trial NCT05174312 study?
This clinical trial studies the following conditions: Acute Decompensated Heart Failure.
What interventions are being tested in trial NCT05174312?
The interventions under investigation include: Reprieve Decongestion Management System (DEVICE), Diuretic (DRUG).
Who is sponsoring clinical trial NCT05174312?
This trial is sponsored by Reprieve Cardiovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05174312 being conducted?
This trial has 16 study locations across Alabama, California, District of Columbia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Decompensated Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05174312's enrollment target sits among peer trials
100 7th of 12 higher than 5 of 12 other Acute Decompensated Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Decompensated Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
RECRUITING · NA
-
DORAYA-HF Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
RAAS Optimization for Acute CHF Patients
COMPLETED · NA
-
Evaluation of Cardiopulmonary Diseases by Ultrasound
COMPLETED · NA
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI